About the study

This is a prospective, multi-national, non-interventional study (NIS) collecting data from postmenopausal women, and adult men, with HR+, HER2- locally advanced or metastatic breast cancer whose tumor harbors a PIK3CA mutation, and who are treated with alpelisib in combination with fulvestrant after disease progression following endocrine therapy as monotherapy, in the real-world setting.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Signed informed consent from the patient or a legally acceptable representative, obtained before any study-related activities are undertaken
2. Patients diagnosed with HR+, HER2
3. locally advanced or metastatic breast cancer with a PIK3CA mutation
4. Patients who have disease progression following endocrine therapy as monotherapy
5. Patients must be postmenopausal women, or men, ≥18 years of age
6. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant

Exclusion criteria

1. Use of alpelisib prior to signing the informed consent form for this study
2. Participation in an interventional study within 30 days prior to the initiation of alpelisib

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.